In the previous study the highest dose of aDLI a patient received is the same as the dose to be initially administered in this study which is 1 x 108 CD3+ cells/kg. However, this research study will also include doses higher than those used in the previous study. Patients in remission will receive the same dose of 1 x 108 CD3+ cells/kg on 4 additional occasions as long as no unacceptable side effects are observed. Patients that are not in remission will receive a dose that is 10 times higher.